Despite Warnings, FDA Approves Humacyte Artificial Blood Vessel

In December 2024, the U.S. Food and Drug Administration (FDA) approved Humacyte’s SYMVESS™, an acellular tissue-engineered vessel designed for use in adult patients requiring vascular repair due to extremity trauma. This approval marks a significant advancement in vascular trauma treatment, offering an off-the-shelf alternative to traditional autologous vein grafts. However, the approval has not been without controversy, as it came despite internal warnings about potential risks associated with the device.​

At Kherkher Garcia, we remain vigilant in monitoring the approval and use of medical devices to ensure patient safety. With the recent FDA approval of Humacyte artificial blood vessels – despite warnings of potential risk – we understand the serious consequences that defective or dangerous medical devices can have on patients’ health. Our experienced product liability attorneys are prepared to assist individuals who suffer injuries due to unsafe medical products.

If you or a loved one experience complications from a defective device, we are here to help you navigate the complexities of product liability claims and fight for the compensation you deserve.

Understanding SYMVESS and Its Intended Use

SYMVESS is a bioengineered vascular conduit developed to address the challenges faced in treating vascular injuries, particularly when autologous vein grafts are unavailable or unsuitable. Traditional treatments often involve harvesting the patient’s own vein, which may not be feasible due to damage or other medical conditions. SYMVESS offers an alternative by providing a ready-to-use vessel that can be implanted without the need for harvesting. ​

FDA Approval Amid Safety Concerns

The FDA’s approval of SYMVESS was accompanied by serious safety concerns. Notably, the device carries a black box warning—the agency’s most severe caution—highlighting risks such as graft rupture and anastomotic failure, which can lead to life-threatening hemorrhage. Additionally, there are concerns about thrombosis (blood clots within the graft) and the potential transmission of infectious diseases due to the use of human and bovine-derived materials in the manufacturing process. ​

Despite these warnings, the FDA proceeded with approval, citing the device’s potential benefits in addressing unmet medical needs in vascular trauma care. The decision has been met with criticism from some quarters, with reports indicating that the approval was granted despite internal staff concerns about the device’s safety profile.

Potential Risks Associated with the Humacyte Artificial Blood Vessel

Patients receiving a Humacyte artificial blood vessel should be aware of the following potential risks:

• Graft Rupture: The implanted vessel may rupture, leading to severe bleeding and necessitating emergency medical intervention.​
• Anastomotic Failure: Failure at the surgical connection points between the graft and the patient’s native vessels can result in loss of graft function and possible hemorrhage.
• Thrombosis: Formation of blood clots within the graft can impede blood flow, potentially leading to graft failure or other complications.​
• Infection Transmission: Due to the use of human donor cells and animal-derived materials, there is a risk, albeit minimized through screening, of transmitting infectious agents.

Legal Implications and Product Liability

The approval of medical devices like SYMVESS that carry significant risks raises important legal considerations, particularly concerning product liability. Manufacturers have a duty to ensure their products are safe and to adequately warn of any potential dangers. Failure to do so can result in liability under various legal theories:

• Design Defects. If a product is inherently unsafe due to its design, manufacturers can be held liable for resulting injuries.​
• Manufacturing Defects. Deviations from the intended design during production that render a product unsafe can also lead to manufacturer liability.​
• Failure to Warn (Marketing Defects). Inadequate instructions or failure to warn consumers about potential risks associated with the product can result in liability.​

In the case of SYMVESS, the presence of a black box warning indicates that the manufacturer and the FDA acknowledge significant risks. However, if patients suffer injuries that they believe are due to undisclosed or underemphasized risks, they may have grounds for a product liability claim.​

Pursuing a Product Liability Claim

Patients who experience adverse effects from medical devices like SYMVESS may consider pursuing legal action. The process generally involves several steps:​

• Consultation with Legal Counsel. Engage an attorney experienced in medical device litigation to evaluate the case’s merits.​
• Medical Evaluation. Obtain a thorough medical assessment to document the injury and its connection to the device.​
• Gathering Evidence. Collect medical records, device information, and any communication with healthcare providers regarding the device.​
• Filing the Claim. If the attorney determines there is a viable case, they will file a lawsuit against the manufacturer, and potentially other parties involved in the device’s distribution and implantation.​
• Litigation Process. The case may go through discovery, negotiations, and potentially a trial to determine liability and damages.​

Kherkher Garcia Fights for Victims of Dangerous Medical Devices

When medical devices fail, the consequences can be devastating. Patients rely on these products to improve their health, but when defects, inadequate warnings, or rushed approvals lead to injury, victims deserve justice. At Kherkher Garcia, we fight for individuals harmed by dangerous medical devices, ensuring that manufacturers, distributors, and other responsible parties are held accountable.

Our legal team has extensive experience handling complex product liability cases, including those involving faulty implants, defective surgical tools, and high-risk pharmaceutical devices. With the recent FDA approval of Humacyte artificial blood vessels – despite concerns about life-threatening complications like graft rupture and thrombosis – patients must be aware of their rights if they experience harm.

Kherkher Garcia thoroughly investigates each case, working with medical experts to determine whether a device was defectively designed, poorly manufactured, or marketed without adequate safety warnings. We help victims pursue compensation for medical expenses, lost wages, pain and suffering, and other damages caused by unsafe medical products.

If you or a loved one have suffered due to a dangerous medical device, you don’t have to face the legal battle alone. Kherkher Garcia is committed to protecting your rights and ensuring that negligent manufacturers are held responsible. Contact us today for a free consultation to discuss your case and explore your legal options. You can start a consultation right now by calling us at 713-333-1030. You can also reach out to us online via our website contact form.

 Image by muhammad.abdullah on Freepik